Noveome Biotherapeutics   Report issue

For profit Phase 1 Phase 2
Founded: Pittsburgh PA United States (2000)

Organization Overview

First Clinical Trial
2009
NCT00886470
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Noveome Biotherapeutics, formerly Stemnion | Noveome Biotherapeutics, Inc

Active Ingredients

Drugs in Phase 2 Trials (3)

amnion-derived cellular cytokine (6 trials)

sodium chloride (5 trials)

st266 (6 trials)

Drugs in Phase 1 Trials (1)

cellulose (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Burns (Phase 2)

Conjunctivitis (Phase 2)

Conjunctivitis, Allergic (Phase 2)

Dermatitis (Phase 1)

Dry Eye Syndromes (Phase 1)

Gingivitis (Phase 1)

Glaucoma (Phase 1)

Inflammation (Phase 2)

Keratoconjunctivitis Sicca (Phase 1)

Ocular Hypertension (Phase 1)

Periodontal Diseases (Phase 2)

Periodontitis (Phase 2)

Radiodermatitis (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 12
  • # of Trial APIs: 4